Table 1.
Demographics (based on 8th edition of AJCC [28]
| Characteristic | Patients (n = 32) |
|---|---|
| Age at diagnosis, median (IQR; range) | 46 (28–55; 16–83) |
| Sex | |
| Female | 22 (68.8%) |
| Male | 10 (31.3%) |
| T stage | |
| 1a | 0 (0%) |
| 1b | 9 (28.1%) |
| 2 | 11 (34.4%) |
| 3a | 11 (34.4%) |
| 3× | 0 (0%) |
| 4b | 1 (3.1%) |
| N stage | |
| N0 | 16 (50.0%) |
| N1 | 0 (0%) |
| Nx | 16 (50.0%) |
| M stage | |
| 0 | 31 (96.9%) |
| 1* | 1 (3.1%) |
| Size, median (IQR; range) | 3.6 (1.8–5.1; 1.2–8.1) |
| Multifocal | |
| Yes | 2 (6.3%) |
| No | 28 (87.5%) |
| Unknown | 2 (6.3%) |
| Vascular invasion | |
| Yes, < 4 blood vessels | 4 (12.5%) |
| Yes, ≥ 4 blood vessels | 8 (25.0%) |
| Yes, unknown number of blood vessels | 5 (15.6%) |
| No vascular Invasion | 14 (43.8%) |
| Unknown | 1 (3.1%) |
| Extrathyroidal extension (microscopic) | |
| Yes | 0 (0%) |
| No | 31 (96.9%) |
| Unknown | 1 (3.1%) |
| I131 cumulative dose, median (IQR; range) | 100 (50–135; 29–692) |
| ATA risk | |
| Low | 18 (56.3%) |
| Intermediate | 0 (0%) |
| High | 11 (34.4%) |
| Unknown | 3 (9.4%) |
| EBRT | |
| No | 30 (93.8%) |
| Neck | 2 (6.3%) |
| Bone | 0 (0%) |
| Systemic Rx-kinase inhibitors | 1 (3.1%) |
| TgAB | |
| Positive | 1 (3.1%) |
| Positive then negative | 8 (25.0%) |
| Duration of follow-up (IQR; range) | 4.3 (2.1–7.9; 0.5–19.9) |
IQR interquartile range (25th to 75th percentiles), range min to max, *M1 patients with metastatic disease at the time of initial therapy